A new treatment option for patients with recurrent or refractory diffuse large B-cell lymphoma The Hospital of Hematology, Chinese Academy of Medical Sciences is currently participating in a clinical study of a fully human monoclonal antibody for the treatment of diffuse large B-cell lymphoma (DLBCL). ü The study is being conducted in more than 170 research centers in 26 countries worldwide. ü The study has been approved by the China Food and Drug Administration (Grant No. 2012L00822) and the Ethics Committee and is being conducted at 20 research centers in Beijing, Shanghai, Tianjin and Guangzhou. The study will use a fully human monoclonal IgG1κ antibody (Ofatumumab) in combination with a controlled salvage chemotherapy regimen of melova followed by autologous stem cell transplantation to observe the benefit in patients with relapsed or refractory DLBCL If you are 18 years of age or older, CD20 positive and have received melova in combination with first-line chemotherapy for relapsed or refractory DLBCL, you may Have the opportunity to participate in the study For those who are screened and eligible to enter the study, the cost of study treatment drugs and related tests will be paid by the sponsor.